208 related articles for article (PubMed ID: 27744089)
21. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).
AbouEzzeddine OF; Haines P; Stevens S; Nativi-Nicolau J; Felker GM; Borlaug BA; Chen HH; Tracy RP; Braunwald E; Redfield MM
JACC Heart Fail; 2015 Mar; 3(3):245-52. PubMed ID: 25742762
[TBL] [Abstract][Full Text] [Related]
22. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial.
Lechner K; Scherr J; Lorenz E; Lechner B; Haller B; Krannich A; Halle M; Wachter R; Duvinage A; Edelmann F
Clin Res Cardiol; 2022 Mar; 111(3):308-321. PubMed ID: 34453204
[TBL] [Abstract][Full Text] [Related]
23. Correlates of Plasma NT-proBNP/Cyclic GMP Ratio in Heart Failure With Preserved Ejection Fraction: An Analysis of the RELAX Trial.
Chiu L; Agrawal V; Armstrong D; Brittain E; Collins S; Hemnes AR; Hill JA; Lindenfeld J; Shah SJ; Stevenson LW; Wang TJ; Gupta DK
J Am Heart Assoc; 2024 Apr; 13(7):e031796. PubMed ID: 38533961
[TBL] [Abstract][Full Text] [Related]
24. Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction.
Barroso MC; Kramer F; Greene SJ; Scheyer D; Köhler T; Karoff M; Seyfarth M; Gheorghiade M; Dinh W
BMC Cardiovasc Disord; 2016 Oct; 16(1):199. PubMed ID: 27769173
[TBL] [Abstract][Full Text] [Related]
25. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension.
Liu LC; Hummel YM; van der Meer P; Berger RM; Damman K; van Veldhuisen DJ; Voors AA; Hoendermis ES
Eur J Heart Fail; 2017 Jan; 19(1):116-125. PubMed ID: 27873388
[TBL] [Abstract][Full Text] [Related]
26. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.
Abernethy A; Raza S; Sun JL; Anstrom KJ; Tracy R; Steiner J; VanBuren P; LeWinter MM
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29650706
[TBL] [Abstract][Full Text] [Related]
27. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
DeVore AD; McNulty S; Alenezi F; Ersboll M; Vader JM; Oh JK; Lin G; Redfield MM; Lewis G; Semigran MJ; Anstrom KJ; Hernandez AF; Velazquez EJ
Eur J Heart Fail; 2017 Jul; 19(7):893-900. PubMed ID: 28194841
[TBL] [Abstract][Full Text] [Related]
28. Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial.
Patel KV; Mauricio R; Grodin JL; Ayers C; Fonarow GC; Berry JD; Pandey A
ESC Heart Fail; 2019 Aug; 6(4):613-620. PubMed ID: 30993916
[TBL] [Abstract][Full Text] [Related]
29. Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction.
Kanagala P; Arnold JR; Cheng ASH; Singh A; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
Int J Cardiovasc Imaging; 2020 Jan; 36(1):101-110. PubMed ID: 31401742
[TBL] [Abstract][Full Text] [Related]
30. Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial.
Patel RB; Mehta R; Redfield MM; Borlaug BA; Hernandez AF; Shah SJ; Dubin RF
J Card Fail; 2020 Mar; 26(3):233-242. PubMed ID: 31931098
[TBL] [Abstract][Full Text] [Related]
31. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
[TBL] [Abstract][Full Text] [Related]
32. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
[TBL] [Abstract][Full Text] [Related]
33. Functional iron deficiency and diastolic function in heart failure with preserved ejection fraction.
Kasner M; Aleksandrov AS; Westermann D; Lassner D; Gross M; von Haehling S; Anker SD; Schultheiss HP; Tschöpe C
Int J Cardiol; 2013 Oct; 168(5):4652-7. PubMed ID: 23968714
[TBL] [Abstract][Full Text] [Related]
34. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
[TBL] [Abstract][Full Text] [Related]
35. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
36. Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction.
Zhang Y; Li SY; Xie JJ; Wu Y
Clin Cardiol; 2020 Jun; 43(6):587-593. PubMed ID: 32212277
[TBL] [Abstract][Full Text] [Related]
37. The correlation of left atrial volume index to the level of N-terminal pro-BNP in heart failure with a preserved ejection fraction.
Kim H; Jun DW; Cho YK; Nam CW; Han SW; Hur SH; Kim YN; Kim KB
Echocardiography; 2008 Oct; 25(9):961-7. PubMed ID: 18771554
[TBL] [Abstract][Full Text] [Related]
38. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
[TBL] [Abstract][Full Text] [Related]
39. Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Zile MR; Anand IS; Packer M; Zannad F; Lam CSP; Janssens S; Jhund PS; Kober L; Rouleau J; Shah SJ; Chopra VK; Shi VC; Lefkowitz MP; Prescott MF; Pfeffer MA; McMurray JJV; Solomon SD
JACC Heart Fail; 2020 May; 8(5):372-381. PubMed ID: 32241619
[TBL] [Abstract][Full Text] [Related]
40. Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
Mohammed SF; Borlaug BA; McNulty S; Lewis GD; Lin G; Zakeri R; Semigran MJ; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
Circ Heart Fail; 2014 Jul; 7(4):580-9. PubMed ID: 24833648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
